A study reports that increasing a protein called neuregulin-1 (NRG1) in the brain significantly reduces symptoms of Alzheimer’s disease (AD) in experimental mice.
NRG1 performs multiple functions in the brain, and it can exist in different forms. Some studies have indicated that it may be a therapeutic target for schizophrenia, Parkinson’s disease and some other brain diseases.
In this study, one of two forms of NRG1 was overexpressed in the hippocampus of a AD mouse model. The researchers then performed Morris water-maze test to study the ability of spatial memory in these mice, and found that both forms of NRG1 elevated the animals’ performance. In addition, the levels of some cellular markers of AD, such as Aβ peptides and plaques, were significantly reduced.